Trusted Resource for Clinical Trials, Protocols & Progress
A Safety Management Plan is a detailed document created by the sponsor (or CRO) that outlines how safety will be managed throughout a clinical trial. It includes procedures for adverse event (AE) and Serious Adverse Event (SAE) identification, assessment, documentation, reporting, and escalation. The plan ensures alignment with GCP, USFDA regulations, and ICH E2A/E6(R2) guidelines.
Click to read the full article.
A Risk Management Plan is a regulatory-required document that identifies, assesses, and outlines strategies to minimize the known and potential risks associated with an investigational medicinal product. It forms part of a broader pharmacovigilance system and aligns with the ICH E2E guidelines on pharmacovigilance planning.
Click to read the full article.
Ensure all risk communications are backed by controlled documents such as:
Click to read the full article.
A safety database is a validated electronic system used by sponsors, CROs, and pharmacovigilance teams to record, manage, and analyze SAEs reported during clinical trials. These systems ensure that safety information is logged, processed, and reported within mandated timelines to health authorities such as the USFDA, EMA, and CDSCO.
Click to read the full article.
Post-marketing signal management refers to the structured process of identifying, validating, prioritizing, and acting upon potential safety signals from various data sources once a product is on the market. This process is governed by regulatory expectations such as those from the EMA, USFDA, and other health authorities worldwide.
Click to read the full article.
According to ICH guidelines, an SAE is considered unexpected if its nature or severity is not consistent with the applicable product information, such as the Investigator Brochure (IB) or Summary of Product Characteristics (SmPC). This includes:
Click to read the full article.
The ISS is a mandatory section within Module 2.7.4 of the Common Technical Document (CTD) submitted to regulatory agencies like the USFDA. It integrates safety data across all clinical studies, including Phase 1, 2, and 3 trials, providing a complete and cumulative assessment of adverse events, serious adverse events, and other safety parameters.
Click to read the full article.
Cross-trial signal detection refers to the identification and validation of safety signals based on aggregated safety data across multiple clinical studies. This approach enhances sensitivity to rare, serious, or cumulative adverse events (AEs) that might not reach a threshold of concern within a single trial.
Click to read the full article.
A safety signal is defined as information that arises from one or multiple sources (clinical, preclinical, spontaneous reports, etc.) suggesting a new potentially causal association, or a new aspect of a known association, between an intervention and an adverse event. Detection of such signals is essential during all phases of clinical trials.
Click to read the full article.
A pharmacovigilance (PV) committee is a cross-functional group of professionals responsible for overseeing the safety of clinical trial participants by reviewing AE trends, validating safety signals, and recommending regulatory or protocol-level actions. These committees may be permanent, like a Safety Management Board (SMB), or ad-hoc Signal Review Committees (SRCs) convened for specific concerns.
Click to read the full article.
